Akrivis is a deep-tech platform company converging marine biotechnology, catechol chemistry, and advanced nanomaterials to develop first-in-class bio-solutions. Operating within the AMTZ MedTech ecosystem, it builds scalable clinical engines that transform biological insights into market-ready therapeutics and medical devices. The company holds 8 filed patents and 23+ validated commercial products, with regulatory clearances from CDSCO, US FDA, and ISO certifications.
Funding
Funding not disclosed
Founders
Product
Problem
Developing first-in-class bio-solutions—from therapeutic devices to regenerative tissue platforms—typically requires integrating multiple specialized scientific disciplines, which creates bottlenecks in translating lab discoveries into scalable, clinically validated products. Many deep-tech ventures struggle to bridge the gap between macro-level surgical applications and micro-level cellular mechanisms, delaying market entry and undermining buyer confidence.
Solution
Akrivis provides a compounding deep-tech platform approach that converges marine biotechnology, catechol chemistry, and advanced nanomaterials into scalable clinical engines. The company operates cGMP giga-scale manufacturing within Asia's premier MedTech zone, enabling seamless transition from laboratory discovery to commercial production. By uniting surgeon-scientist insights with cancer biology expertise, Akrivis develops non-invasive alternatives and precision regenerative platforms. Their flagship products include TympanoSeal™, SynExo™, EXOGLAM™, and HEMOSOME, each designed to deliver clinical efficacy and commercial scalability. The company maintains active regulatory clearances across CDSCO, US FDA, and European standards to eliminate buyer skepticism at first contact.
Target Audience
Primary customers include medical device manufacturers, pharmaceutical companies, surgical centers, and cosmeceutical brands seeking validated, large-scale bio-solution manufacturing and regulatory-compliant product development.
Features
- Eight filed patents and 23+ validated commercial products across therapeutic, device, and cosmeceutical portfolios
- cGMP giga-scale manufacturing capability at Asia's premier MedTech zone, AMTZ
- CDSCO licensed full medical device and cosmetic pathway with US FDA registered facility status
- ISO 9001:2015 and ISO 22716:2007 certifications, plus TÜV Rheinland independent elemental validation
- Active BIS MHD-20 seat drafting national standards aligned with EN ISO 13485 and European MDR
- Platform-based R&D model where each product expresses an underlying body of knowledge that compounds over time